Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 759 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cystic Fibrosis Clear all
Completed Phase 1 Interventional

Repeatability and Response Study of Absorptive Clearance Scans

NCT01887197
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Absorptive clearance scan, inhaled hypertonic saline (7%), mannitol inhalation powder
Other · Drug
Lead sponsor
Tim Corcoran
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00112359
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg three times a day (TID), Placebo three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
40
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Not applicable Interventional

Comprehensive Exercise Training Program During Hospitalization for an Acute CF Exacerbation

NCT01759342
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aerobic exercise, Resistance exercise, Flexibility and postural exercise, Balance exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01313624
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Jun 7, 2026, 4:28 AM EDT
Not listed Phase 3 Interventional

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

NCT03051490
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Liprotamase, porcine PERT
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Jun 7, 2026, 4:28 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

NCT05006573
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Benralizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Newport Beach, California • Northridge, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 1 Interventional

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

NCT00910351
View directory record Official record
Conditions
Pseudomonas Infection
Interventions
Ciprofloxacin (Cipro, BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Not applicable Interventional

Integrating Supportive Care in Cystic Fibrosis

NCT02668575
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Supportive Care Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis

NCT05225805
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lefamulin
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Kansas City, Kansas • Boston, Massachusetts • Valhalla, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

NCT00712166
View directory record Official record
Conditions
Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
Interventions
AZLI 75 mg three times daily (TID), Placebo three times daily (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2010 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Ataluren (PTC124) in Cystic Fibrosis

NCT01140451
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jun 7, 2026, 4:28 AM EDT
Completed No phase listed Observational

Zinc Status and Growth in Cystic Fibrosis

NCT04302428
View directory record Official record
Conditions
Cystic, Fibrosis
Interventions
Serum Zn, Red Blood Cell Zn
Biological
Lead sponsor
Indiana University
Other
Eligibility
3 Months to 3 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2023 · Synced Jun 7, 2026, 4:28 AM EDT
Completed No phase listed Observational

Viral Pathogenesis of Early Cystic Fibrosis Lung Disease

NCT01973192
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 4 Months
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Jun 7, 2026, 4:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Breath Condensate Study in Patients With Cystic Fibrosis.

NCT02056132
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Exhaled Breath Condensate
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD)

NCT01023048
View directory record Official record
Conditions
Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs)
Interventions
preimplantation diagnosis
Other
Lead sponsor
Natera, Inc.
Industry
Eligibility
Up to 40 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

NCT01707290
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

NCT05069597
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Pancreatitis
Interventions
CREON
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Mobile, Alabama • Madera, California • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 4 Interventional Results available

IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy

NCT02918409
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Colistin, Tobramycin
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis

NCT02866721
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Mesenchymal Stem Cells
Biological
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cystic Fibrosis and Endothelial Function: At Rest and During Exercise

NCT01772758
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
BH4 5mg, BH4 20mg, Antioxidant Cocktail
Drug · Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
7 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

NCT02709109
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-371 + HS, Hypertonic saline, Placebo, Orkambi, VX-371
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Little Rock, Arkansas • Oakland, California • Gainesville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Jun 7, 2026, 4:28 AM EDT
Recruiting No phase listed Observational

Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)

NCT07102043
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 4 Interventional Results available

Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients

NCT02178540
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, Tobi Podhaler
Drug · Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis

NCT02465450
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
JBT-101 (lenabasum), Placebo
Drug · Other
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Jun 7, 2026, 4:28 AM EDT